Information Provided By:
Fly News Breaks for May 29, 2019
May 29, 2019 | 06:22 EDT
Goldman Sachs analyst Paul Choi upgraded Radius Health to Buy from Neutral after assuming coverage of the name. He raised his price target for the shares to $38 from $26. The analyst believes Tymlos will continue to gain share with the abaloparatide patch "expanding the market significantly." Further, elacestrant provides Radius "attractive optionality," Choi tells investors in a research note.
News For RDUS From the Last 2 Days
There are no results for your query RDUS